Theorem Clinical Research


UCB to sell generics business to private equity firms Advent, Avista Capital for $1.525 billion

Monday, November 10, 2014 12:26 PM

Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, have agreed to acquire UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals (KU). UCB is a multinational biopharmaceutical manufacturing company headquartered in Brussels, Belgium.

More... »

Quest Diagnostics

Blaze Bioscience raises $9.8M in Series A financing

Monday, February 25, 2013 10:28 AM

Blaze Bioscience, a Seattle-based biotechnology company focused on cancer, has completed a Series A financing totaling $8.5 million, bringing the total funds raised since inception to $9.8 million.

More... »

Takeda to cut 2,800 jobs as it absorbs Nycomed

Wednesday, January 18, 2012 12:21 PM

Osaka, Japan-based Takeda Pharmaceutical plans to consolidate its R&D site operations and cut its workforce by 2,800 to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture.

More... »

Regeneron names LaRosa senior VP

Tuesday, September 6, 2011 12:44 PM

Regeneron Pharmaceuticals has named Joseph J. LaRosa senior vice president, general counsel and secretary. LaRosa will be responsible for overseeing all legal affairs, including general corporate legal matters, intellectual property and corporate compliance, and will report to Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer.

More... »

Takeda acquires Nycomed for $13.7 billion

Tuesday, August 2, 2011 12:50 PM

Japanese drug maker Takeda Pharmaceutical secured EU approval for its $13.68 billion acquisition of privately owned Nycomed to reinforce its presence in emerging markets, according to Reuters.

More... »

Takeda acquires Nycomed

Thursday, May 19, 2011 10:45 AM

Japan-based Takeda Pharmaceutical has agreed to buy Switzerland-based Nycomed for $13.6 billion, making it a wholly-owned subsidiary of Takeda.

More... »

Takeda denies takeover of Nycomed

Friday, May 13, 2011 11:35 AM

Japan-based Takeda Pharmaceutical has denied rumors of a $12.3 billion takeover of Switzerland-based Nycomed, according to Pharma Times.

More... »

Nycomed and Almirall partner to market COPD drug

Thursday, May 5, 2011 11:54 AM

Nycomed and Almirall will become marketing partners for the chronic obstructive pulmonary disease (COPD) treatment Daxas. The two firms have entered into a co-branding agreement covering Spain for Daxas (roflumilast), Nycomed's once-daily COPD tablet, according to Pharma Times.

More... »

Nycomed/Forest drug gains FDA approval

Tuesday, March 8, 2011 10:45 AM

The FDA has approved Nycomed and partner Forest Laboratories’ chronic obstructive pulmonary disease drug roflumilast, according to PharmaTimes.

More... »

Ecron Acunova Founder Steps Down

Friday, April 24, 2009 08:29 AM

Ecron Acunova, a CRO based out of Germany, India and the United States, appointed Antal Hajos managing director and CEO Europe, replacing ECRON founder and CEO Klaus Wiedey, who will serve as an advisor to the company. In his new role, Hajos will oversee all business, strategic and operational aspects of the European operations. Prior to joining Ecron Acunova last year, Hajos was director of global clinical operations with Altana Pharma and later CEO of Altana/Nycomed’s research and development center and Indian affiliate in Mumbai, India.

More... »


March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs